

# Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

NCT06360289

---

Status	RECRUITING
Sponsor	Alyniam Pharmaceuticals
Enrollment	500 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Carrier of a documented pathogenic TTR variant confirmed with genotyping with predicted disease onset within 5 years and not diagnosed with hATTR amyloidosis with polyneuropathy
- OR
- Confirmed diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR variant confirmed with genotyping
- Participant is able to understand the study and does not oppose participating in the study after reviewing the content of the PIS provided.

### Exclusion (3)

- A known condition (other than hATTR amyloidosis) that can cause nerve damage and affect NfL levels
- Estimated glomerular filtration rate (eGFR)  $< 45$  milliliters per minute per 1.73 meters squared (mL/min/1.73 m<sup>2</sup>)
- Currently enrolled in a clinical study for any investigational agent.

## Locations (1 total)

---

Centre Hospitalier Universitaire (CHU) Le Kremlin-Bicêtre Assistance Publique-Hôpitaux de Paris (APHP), Paris, Île-de-France Region, France